Zobrazeno 1 - 10
of 827
pro vyhledávání: '"G. Burnett"'
Autor:
Philip D Greenberg, Valentin Voillet, Raphael Gottardo, Kristin G Anderson, Breanna M Bates, Madison G Burnett, Susan L Ruskin, Yapeng Su, Magdalia L Suarez Gutierrez
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/02aa15847e644c8caf9301b40b6a786b
Autor:
Nikki M. McCormack, Eric Villalón, Coralie Viollet, Anthony R. Soltis, Clifton L. Dalgard, Christian L. Lorson, Barrington G. Burnett
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 12, Iss 4, Pp 1098-1116 (2021)
Abstract Background Spinal muscular atrophy is an inherited neurodegenerative disease caused by insufficient levels of the survival motor neuron (SMN) protein. Recently approved treatments aimed at increasing SMN protein levels have dramatically impr
Externí odkaz:
https://doaj.org/article/f555774c644749c7bb8839ffe2c95e25
Autor:
Stephen G. Burnett
Christian Hebraism in early modern Europe has traditionally been interpreted as the pursuit of a few exceptional scholars, but in the sixteenth century it became an intellectual movement involving hundreds of authors and printers and thousands of rea
Autor:
Guzal Khayrullina, Kasey E. Moritz, James F. Schooley, Naheed Fatima, Coralie Viollet, Nikki M. McCormack, Jeremy T. Smyth, Martin L. Doughty, Clifton L. Dalgard, Thomas P. Flagg, Barrington G. Burnett
Publikováno v:
Skeletal Muscle, Vol 10, Iss 1, Pp 1-13 (2020)
Abstract Spinal muscular atrophy (SMA) is a neurodegenerative disease characterized by loss of alpha motor neurons and skeletal muscle atrophy. The disease is caused by mutations of the SMN1 gene that result in reduced functional expression of surviv
Externí odkaz:
https://doaj.org/article/40e9130eb6944548a569a8859af78a5f
Autor:
Philip D Greenberg, Kristin G Anderson, Shannon K Oda, Breanna M Bates, Madison G Burnett, Magdalia Rodgers Suarez, Susan L Ruskin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 3 (2022)
Background In the USA, more than 50% of patients with ovarian cancer die within 5 years of diagnosis, highlighting the need for therapeutic innovations. Mesothelin (MSLN) is a candidate immunotherapy target; it is overexpressed by ovarian tumors and
Externí odkaz:
https://doaj.org/article/16c482feb17b4df89dbc5b52b72fb431
Autor:
Karen G. Burnett, Louis E. Burnett
Publikováno v:
The Biological Bulletin. 243:120-133
Autor:
Dean Phillip Bell, Stephen G. Burnett
This book represents a multi-disciplinary approach to the problem of the Jews and the German Reformation. The contributions come from both senior and emerging scholars, from North America, Israel, and Europe, to ensure a breadth in perspective. The e
Autor:
Philip D. Greenberg, Raphael Gottardo, Charles W. Drescher, Ingunn M. Stromnes, Christopher B. Morse, Shannon K. Oda, Nicolas M. Garcia, Madison G. Burnett, Edison Y. Chiu, Breanna M. Bates, Valentin Voillet, Kristin G. Anderson
Figure S1: MSLN-specific engineered CD8 T cells induce cell death in HGSOC cell lines.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fd28b9c0a947ea42642ccd5dc082597
https://doi.org/10.1158/2326-6066.22543438
https://doi.org/10.1158/2326-6066.22543438
Autor:
Philip D. Greenberg, Raphael Gottardo, Charles W. Drescher, Ingunn M. Stromnes, Christopher B. Morse, Shannon K. Oda, Nicolas M. Garcia, Madison G. Burnett, Edison Y. Chiu, Breanna M. Bates, Valentin Voillet, Kristin G. Anderson
Figure Legends for Supplemental Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::975efb2816191d40d7b2661b26c8ea6e
https://doi.org/10.1158/2326-6066.22543414.v1
https://doi.org/10.1158/2326-6066.22543414.v1
Autor:
Philip D. Greenberg, Raphael Gottardo, Charles W. Drescher, Ingunn M. Stromnes, Christopher B. Morse, Shannon K. Oda, Nicolas M. Garcia, Madison G. Burnett, Edison Y. Chiu, Breanna M. Bates, Valentin Voillet, Kristin G. Anderson
Adoptive T-cell therapy using high-affinity T-cell receptors (TCR) to target tumor antigens has potential for improving outcomes in high-grade serous ovarian cancer (HGSOC) patients. Ovarian tumors develop a hostile, multicomponent tumor microenviron
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c02eecee4fe98f8dd53a22107cf78629
https://doi.org/10.1158/2326-6066.c.6550249.v1
https://doi.org/10.1158/2326-6066.c.6550249.v1